Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 19Lung Neoplasms 15Multiple Myeloma 13Leukemia, Myeloid, Acute 12Glioma 10Wilms Tumor 9Lymphoma, Non-Hodgkin 9Breast Neoplasms 9Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Osteosarcoma 8Neuroblastoma 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Rhabdoid Tumor 7Hepatoblastoma 7Rhabdomyosarcoma 6Ovarian Neoplasms 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Sarcoma, Ewing 5Rectal Neoplasms 5Pancreatic Neoplasms 5Leukemia, Myelomonocytic, Chronic 5

Interventions

pembrolizumab 7Nivolumab 7Specimen Handling 6Mitomycin 6Magnetic Resonance Spectroscopy 6Capecitabine 6Radiotherapy 5Fluorouracil 4Drug Therapy 4Biopsy 4Radiation 3Paclitaxel 3Ipilimumab 3Fluorodeoxyglucose F18 3Carboplatin 3dehydroftorafur 2atezolizumab 2aldesleukin 2Tomography, X-Ray Computed 2Sigmoidoscopy 2Radiotherapy, Intensity-Modulated 2Proctoscopy 2Mitozytrex 2Colonoscopy 2CTLA-4 Antigen 2Adoptive Transfer 2trastuzumab deruxtecan 1spartalizumab 1enzalutamide 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × X-Rays × 1 year × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡